Previous close | 2.0485 |
Open | 1.9114 |
Bid | 0.0000 x N/A |
Ask | 0.0000 x N/A |
Day's range | 1.9114 - 1.9460 |
52-week range | 1.9114 - 1.9460 |
Volume | |
Avg. volume | N/A |
Market cap | 429,060 |
Beta (5Y monthly) | 0.30 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
TOULOUSE, France & LAKELAND, Mich., February 03, 2023--Regulatory News: ABIONYX Pharma (FR0012616852 - ABNX - eligible for PEA PME), a new generation biotech company dedicated to the discovery and development of innovative therapies for patients, announced today that it has been informed by TVM Capital of the total sale of their shares on the market due to the liquidation of their funds that have reached maturity.
TOULOUSE, France & LAKELAND, Mich., January 16, 2023--ABIONYX Pharma (FR0012616852 – ABNX – PEA PME eligible), a new generation biotech company dedicated to the discovery and development of innovative therapies for patients, today reported that the pilot Phase 2a clinical trial evaluating CER-001, the only natural recombinant apoA-I, as a treatment for septic patients at high risk of developing Acute Kidney Injury (AKI) met its primary objective. There are no approved treatments for septic patie
TOULOUSE, France & LAKELAND, Mich., January 13, 2023--Regulatory News: ABIONYX Pharma (FR0012616852 - ABNX - PEA PME eligible), a new generation biotech company dedicated to the discovery and development of innovative therapies for patients, today announces its financial agenda for 2023.